Reposted by haysamrady
Apixaban and warfarin being similar is also a red flag
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial - PubMed
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2025_04_09_ASN0000000000000495.mp3 …
pubmed.ncbi.nlm.nih.gov
November 26, 2025 at 11:10 PM
Apixaban and warfarin being similar is also a red flag
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky